Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Authors
Keywords
B cells, Fatigue, Chronic fatigue syndrome, Patients, Mental health and psychiatry, Autoimmune diseases, Polymerase chain reaction, Psoriasis
Journal
PLoS One
Volume 6, Issue 10, Pages e26358
Publisher
Public Library of Science (PLoS)
Online
2011-10-20
DOI
10.1371/journal.pone.0026358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care
- (2011) Luis C Nacul et al. BMC Medicine
- Absence of XMRV Retrovirus and Other Murine Leukemia Virus-Related Viruses in Patients with Chronic Fatigue Syndrome
- (2011) C. H. Shin et al. JOURNAL OF VIROLOGY
- Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses
- (2011) Brent C Satterfield et al. Retrovirology
- No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected
- (2011) K. Knox et al. SCIENCE
- Recombinant Origin of the Retrovirus XMRV
- (2011) T. Paprotka et al. SCIENCE
- A formal analysis of cytokine networks in Chronic Fatigue Syndrome
- (2010) Gordon Broderick et al. BRAIN BEHAVIOR AND IMMUNITY
- A short review on the psychoneuroimmunology of posttraumatic stress disorder: From risk factors to medical comorbidities
- (2010) Thaddeus W.W. Pace et al. BRAIN BEHAVIOR AND IMMUNITY
- The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases
- (2010) Nichola Cooper et al. BRITISH JOURNAL OF HAEMATOLOGY
- B-cell targeted therapies in human autoimmune diseases: an updated perspective
- (2010) Michael J. Townsend et al. IMMUNOLOGICAL REVIEWS
- B cells as therapeutic targets in SLE
- (2010) Iñaki Sanz et al. Nature Reviews Rheumatology
- Long-Lived Plasma Cells and Memory B Cells Produce Pathogenic Anti-GAD65 Autoantibodies in Stiff Person Syndrome
- (2010) Marta Rizzi et al. PLoS One
- Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors
- (2010) S.-C. Lo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Infection, Vaccination, and Autoantibodies in Chronic Fatigue Syndrome, Cause or Coincidence?
- (2009) Oscar-Danilo Ortega-Hernandez et al. Annals of the New York Academy of Sciences
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
- (2009) K. R. Carson et al. BLOOD
- Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
- (2009) Øystein Fluge et al. BMC Neurology
- Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome
- (2009) V. C. Lombardi et al. SCIENCE
- Evidence of inflammatory immune signaling in chronic fatigue syndrome: A pilot study of gene expression in peripheral blood
- (2008) Anne L Aspler et al. Behavioral and Brain Functions
- Rituximab: Beyond Simple B Cell Depletion
- (2008) A. Kessel et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- A review of the current use of rituximab in autoimmune diseases
- (2008) Hakan M. Gürcan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started